Portfolio company
Melius Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops pharmaceutical treatments for chronic cough in patients with idiopathic pulmonary fibrosis.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Celea Therapeutics
The company develops deupirfenidone, an antifibrotic medicine for patients with idiopathic pulmonary fibrosis and other serious respiratory diseases.
Avalyn Pharma
The company develops inhaled medicines to treat patients with rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Attenua
This company develops small-molecule medicines for patients suffering from chronic respiratory disorders, particularly chronic cough.
Calluna Pharma
This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.
MDI Therapeutics
This pharmaceutical company develops serpin-based therapies to treat patients with chronic fibrosis, inflammatory diseases and fibroproliferative disorders.
Sequel Therapeutics
This pharmaceutical company develops and acquires medicines for patients in specific therapeutic areas.
Promedior
This biotechnology company develops drug therapies to treat rare fibrotic diseases for patients with conditions such as idiopathic pulmonary fibrosis and myelofibrosis.
Mereo BioPharma
The company develops clinical-stage therapies for patients with rare diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.